At this year’s European Congress on Obesity (ECO), during a poster session, researchers presented an analysis of the effects of survodutide in a state-of-the-art translational mouse model of advanced diabetic kidney disease (DKD). The findings raise the possibility that survodutide could eventually compete in both obesity/metabolic disease markets and kidney disease markets if human trials confirm these effects. The animal model gives a proof-of-concept signal: the drug improved both metabolic markers and kidney injury measures in a severe diabetic kidney disease model. That makes the result scientifically important because it suggests the mechanism may be relevant to human disease, not just to isolated cells or artificial lab systems.
The analysis presented at ECO highlighted that, in a translational mouse model of advanced DKD, survodutide improved albuminuria, glomerulosclerosis, kidney hypertrophy, inflammation, and kidney structure, while also lowering body weight, glucose, haemoglobin A1C, and insulin levels.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The strongest clinical signal is that survodutide affected both upstream metabolic drivers and downstream renal injury. It reduced albuminuria and glomerulosclerosis, and it also reversed tubular-glomerular detachment and lowered kidney volume, which points to a broader disease-modifying profile rather than a purely symptomatic effect. This is significant because chronic kidney disease (CKD) therapies are increasingly criticised for whether they can slow structural damage, not just improve biomarkers. The data also supports a mechanistic rationale: glucagon receptor signalling appears impaired in CKD, and survodutide’s dual glucagon and glucagon-like peptide 1 receptor agonist (GCGR/GLP-1) activity may address both metabolic dysfunction and renal pathology. If these findings translate into humans, the drug could become relevant for patients with obesity, diabetes, and CKD risk, not just for glycemic or weight management.
Survodutide is a long-acting dual GCGR/GLP-1 aiming to mimic the metabolic actions of oxyntomodulin. GLP-1 receptor agonists have been widely demonstrated to improve glycemic control and have been linked to modest but clinically relevant weight loss in patients. Glucagon, although known to counteract the GLP-1 effect on blood glucose levels, is believed to induce fat breakdown and produce greater weight loss than GLP-1. It acts on both the GLP-1 and glucagon receptors.
